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RESUMEN
Objetivos: Sintetizar derivados halogenados sobre la base nitrogenada, sus respectivos derivados tipo 
éster o amida de todos los grupos hidroxilo y amina presentes en los nucleósidos uridina y citarabina, y 
evaluar su actividad citotóxica sobre una línea celular de cáncer de mama.
Metodología: primero se realizó la reacción de halogenación en la posición 5 de la base nitrogenada, 
posteriormente se formaron los ésteres y amidas de todos los grupos hidroxilos y amino presentes en 
los nucleósidos. Además, se preparó el derivado acetónido con catálisis ácida. Los compuestos se carac-
terizaron por espectroscopía de resonancia magnética nuclear (RMN 1H y RMN 13C) y espectrometría 
de masas por inyección directa en modo positivo. Los derivados se evaluaron sobre líneas celulares de 
tumor de Ovario de Hámster Chino (CHO) y de cáncer de mamá (MCF-7).
Resultados: Se obtuvieron 4 derivados mono-halogenados con cloro y bromo de la uridina y citarabina, 
respectivamente, sus respectivos derivados per-acetilados, los nucleósidos per-acetilados y el acetónido 
de la uridina; los compuestos se obtuvieron con rendimientos superiores a 90%. Los nucleósidos per-
acetilados, y los derivados per-acetilados y halogenados no exhibieron una inhibición significativa de 
la viabilidad celular en ambas líneas celulares, sin embargo, de estos, los derivados per-acetilados y 
halogenados presentaron mayor actividad citotóxica que los respectivos nucleósidos per-acetilados. El 
derivado acetónido de la uridina mostró citotoxicidad significativa sobre ambas líneas celulares.
Conclusiones: se obtuvieron los nucleósidos per-acetilados y los respectivos derivados clorados y bro-
mados de estos, con rendimientos altos, sin embargo, estos compuestos no exhibieron una actividad 
anti-proliferativa significativa (p˂0,05), posiblemente debido a una baja activación intra-celular de los 
nucleósidos.
Palabras claves: actividad citotóxica, cáncer de mama, nucleósidos anticancerosos, reacciones de esteri-
ficación y halogenación, uridina y citarabina.
ABSTRACT
Objectives. To make the synthesis of halogenated derivatives on the nitrogenous base and their respec-
tive acyl ester and amide type derivatives for all hydroxyl and amine groups of the uridine and cytara-
bine nucleosides, and evaluate cytotoxicity against breast cancer cell line.
Methods. First, it was accomplished the halogenation reaction on the 5-position of the nitrogenous base, 
subsequently, the ester and amide derivatives were performed for all hydroxyl and amine group present 
in the nucleosides. Besides, the uridine acetonide derivatives as prepared by acid catalysis. The prod-
ucts were characterized by nuclear magnetic resonance spectroscopy (1H RMN y 13C RMN) and mass 
spectrometry in positive mode by direct injection. Derivatives were evaluated in Chinese hamster ovary 
(CHO-K1) and human breast cancer (MCF-7) cell lines.
Results. The four derivatives were obtained with chlorine and bromine for the uridine and cytarabine, 
respectively, their respective per-acetylated derivatives, the per-acetylated nucleoside and the uridine 
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acetonide; the compounds were obtained with efficiency over 
90%. The per-acetylated nucleosides and the halogenated and 
per-acetylated derivatives did not show inhibitory effects on cell 
viability in MCF-7 cell line. However, the per-acetylated and halo-
genated derivatives presented a higher cytotoxic activity than their 
respective per-acetylated nucleoside. The uridine 3’,4’-acetonide 
showed a significant cytotoxicity on both cell lines.
Conclusions. The per-acetylated nucleoside, and the respective 
halogenated derivatives with chlorine and bromine were obtained 
with high yields, nevertheless, these compounds did not exhibit 
a significant anti-proliferative activity (p˂0.05), possibly due to a 
low intra-cellular activation. 
Keywords: anticancer nucleoside, breast cancer, cytotoxic activity, 
esterification and halogenation reactions, uridine and cytarabine.
INTRODUCTION
Nucleoside and analog drugs have been widely used in 
cancer chemotherapy since the 1960’s for soft (leukemia 
and lymphoma non-Hodking) and solid (lung, liver, breast, 
among others) tumors treatment. These drugs exhibit sev-
eral action mechanisms such as: disruption of nucleic ac-
ids synthesis, incorporation and demethylation of DNA 
fragments and inhibition of necessary nucleoside synthe-
sis. Furthermore, they can present activation in cytoplasm 
of apoptosis factors and destabilization of mitochondrial 
membrane1-6.
The nucleoside anticancer drugs show several pharma-
codynamic problem including low cellular incorporation 
across transporter channels, intracellular inactivation by 
nucleoside deaminase, degradation by ecto-nucleotidase 
enzymes, higher elimination through transporter channels 
and vesicles, among others. Moreover, they present very 
pharmacokinetic disadvantages such as low selectivity by 
cancer cell, higher chemical lability and biological degrada-
tion and inactivation in blood plasma3-8. Due to the consid-
erable disadvantages of these drugs, it is recommendable 
that they are administered in higher doses by endovenous 
via; however, this administration form is responsible of the 
majority of many side effects (gastrointestinal disorder, 
neurotoxicity, nephrotoxicity and hepatotoxicity, among 
others) of the anticancer nucleoside3-8.
In this sense, a substantial number of studies are focused 
on the synthesis of nucleoside derivatives with anticancer 
potential, that present better physicochemical and/or bi-
ological properties, by performing lipophilic derivatives 
with aliphatic and aromatic acids and forming conjugates 
with terpenoids, heterocycles and polymers, to accomplish 
this, aliphatic diacids and phosphate are commonly used 
as linkage. With these derivatives, the purpose is to avoid 
the enzymatic or the chemical degradation localized in the 
gastrointestinal tissue, blood plasma or cytoplasm and to 
achieve higher cellular uptake through the cell membrane 
transport5-10. 
Other studies focused on the nucleoside and their analogs 
search, show better pharmacokinetic and pharmacody-
namics advantages as well as an enhancement as an an-
timetabolite. These studies demonstrate that the natural 
and synthetic derivatives of the uridine (mainly phospho-
rylated, sulphated and glycosylated compounds), a natural 
and necessary nucleoside, have cellular regulatory func-
tions, for instance, glycosyltransferase cofactors inhibition, 
purinergic receptor agonists, energetic reserve (as UTP can 
accomplish ATP functions), DNA polymerase inhibition, 
among others10-13. Uridine synthetic derivatives with lipo-
philic substituents (C-3’-ethynyluridine, sterols, aromatic 
and aliphatic acids, among others) and diverse monosac-
charide positions have exhibited cytotoxic activities in sev-
eral tumor cell lines or better physicochemical properties 
with biomembrane models interaction14-18.
Furthermore, the uridine triacetate has shown modulating 
effects on the neurotoxicity, gastrointestinal disorders and 
cardiotoxicity when this is used in combinate chemother-
apy with antiviral (Stavudine) and anticancer (Capecit-
abine, better known as fluorouracil) drugs. This uridine 
triacetate, known as Vistogard®, was approved by US Food 
and Drugs Administration (FDA) to the treatment of over-
doses with these antiviral and anticancer nucleosides when 
they are administered for long-term19,20.
EXPERIMENTAL
Chemical
All solvents were employed at reagent grade. Uridine 
and cytarabine at 99% purity (Alfaesar) were employed 
as substrate, acetic anhydride at 99% (Merck) as agent 
for per-esterification reaction,4-N,N-dimethylamino-pyri-
dine (DMAP) at 99% (Alfaesar) as nucleophilic catalyst, 
N-chloro-succinimide (NCS) and N-bromo-succinimide 
(NBS) were used for the halogenation reaction. The halo-
genated and/or per-acetylated derivatives of uridine and 
cytarabine were purified by column chromatography and 
thin layer chromatography using normal phase with di-
chloromethane/methanol and ethyl acetate/acetone mix-
tures as eluents of the halogenation reaction and per-acetyl-
ation, respectively. All nucleoside derivatives, halogenated 
and/or per-acylated, were characterized by a nuclear mag-
netic resonance spectroscopy on the Bruker NMR-300 and 
the Bruker Ascend III HD 600 MHz spectrometers, where 
tetramethylsilane (TMS) was used as internal standard, us-
ing deuterated dimethyl sulfoxide (DMSO-d6) and deuter-
ated chloroform (CDCl3) as solvents. The mass spectrom-
etry analysis was performed on the Agilent 6300-LC/MS 
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(electrospray ionization (ESI) and Ion-Trap analyzer) and 
on the Agilent 6100-LC/MS (electrospray ionization (ESI) 
and Single Quadrupole analyzer) equipment’s, by direct 
injection in positive mode.
Uridine 3’,4’-acetonide (Csint)
Uridine (300 mg) was aggregated to an acetone acidulat-
ed solution with sulfuric acid4,13,17. The product (figure 1) 
was obtained as yellow solid (90% yield). 1H NMR (300 
MHz, DMSO-d6), δ ppm (multiplicity; integration; J (Hz); 
position): 1.26 (s; 3H; acetonide ring), 1.48 (s; 3H; acetonide 
ring), 3.57 (m; 2H; H-6’ of ribose ring), 4.06 (q; 1H; J=4.2; 
H-5’ ribose ring), 4.74 (dd; 1H; J=6.3 y 3.5; H-4’ ribose ring), 
4.89 (dd; 1H; J=6.3 y 2.6; H-3’ ribose ring), 5.63 (d; 1H; J=8.0; 
H-5 uracil ring), 5.82 (d; 1H; J=2.6; H-2’ ribose ring), 7.79 
(d; 1H; J=8.1; H-6 uracil ring). Other NMR (13C and 2D cor-
relations) spectroscopy characterization as was reported 
elsewhere17. ESI-MS (positive mode) m/z: Calculated for 
C12H16N2O6: 284.2652; found, 307.1 [M+Na]
+.
Figure 1. Reaction scheme and chemical structures of uridine derivatives.
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3’,4’-acetonide-6’-O-succinyl uridine (D4)
1.0 equivalents of succinic anhydride and DMAP in cat-
alyst amount was added to uridine acetonide (300 mg) 
solution in DCM/pyridine mix4,9,17. The product (figure 1) 
was obtained as pale-yellow solid (quantitative yield). 1H 
NMR (300 MHz, DMSO-d6), δ ppm (multiplicity; integra-
tion; J (Hz); position): 1.26 (s; 3H; acetonide), 1.48 (s; 3H; 
acetonide), 2.60 (m; 4H; succinic acid), 4.40 (m; 3H; H-6’ y 
H-5’ ribose ring), 4.78 (m; 1H; H-4’ ribose ring), 4.93 (m; 
1H; H-3’ ribose ring), 5.62 (d; 1H; J=8.0; H-5 uracil ring), 
5.81 (d; 1H; J=2.6; H-2’ ribose ring), 7.80 (d; 1H; J=8.1; H-6 
uracil ring). Other NMR (13C and 2D correlations) spectros-
copy characterization as was reported previously17. ESI-MS 
(positive mode) m/z: Calculated for C16H20N2O9: 384.338; 
found, 407.3 [M+Na]+.
Per-acetylation reaction
The nucleoside (300 mg) was dissolved in an acetic anhy-
dride/DMF/TEA (1:1:1) mixture, followed by the addition 
of DMAP (5 mol-%). The reaction mixture was stirred at 
room temperature between 6-8 hours 4,9,16. For chemical re-
action see figures 2 and 3.
3’,4’,6’-O-triacetyl-uridine or uridine triacetate (C1)
The product was obtained as yellow solid (quantitative 
yield). 1H-NMR (300 MHz; DMSO-d6), δ ppm (multiplicity; 
integration; J (Hz); position): 2.04 (d; 6H; H-2” acetyl linked 
to O-3’ and O-6’ ribose ring (R.R)), 2,07 (s; 3H; position 
H-2” acetyl linked to O-4’ ribose ring), 4.25 (m; 3H; H-6’ 
and H-5’ ribose ring), 5.33 (m; 1H; H-4’ ribose ring), 5.44 
(m; 1H; H-3’ ribose ring), 5.72 (d; 1H; J=8.0; H-5 uracil ring), 
5.87 (d; 1H; J=5.1; H-2’ ribose ring), 7.69 (d; 1H; J=8.1; H-6 
uracil ring). Other NMR (13C and 2D correlations) spectros-
copy characterization as was reported elsewhere16. ESI-MS 
(positive mode) m/z: Calculated for C15H18N2O9: 370.3114; 
found, 393.1 [M+Na]+.
Halogenation reaction
The halogenation agent (NCS or NBS) was added (1.1 
equivalents) on a nucleoside solution (1 mmol) in DMF, the 
reaction mix was stirred at room temperature for 8 hours 
(for chemical reaction see figures 2 and 3)21.
5-Bromo-uridine
1H-NMR (600 MHz, d6), δ ppm (multiplicity; integration; J 
(Hz); position): 3.57 (d, 1H; J=12.1; H-6’ ribose ring), 3.69 (d; 
H; J = 12.1; H-6’ ribose ring), 3.86 (d; J = 2.5; 1H; H-5’ ribose 
ring), 3.98 (q; J = 4.8; 1H; H-4’ ribose ring), 4.04 (q; J = 4.6; 
1H; H-3’ ribose ring), 5.73 (d; J = 4.3; 1H; H-2’ ribose ring), δ 
8.48 (s; 1H; H-6 uracil ring). 
5-Chloro-uridine
1H-NMR (600 MHz, d6), δ ppm (multiplicity; integration; J 
(Hz); position): 3.58 (d; J = 10.4; 1H; H-6’ ribose ring), 3.68 
(d; J = 12.0; 1H; H-6’ ribose ring), 3.86 (d; J = 2.2; 1H; H-5’ 
ribose ring), 3.99 (dt; J = 14.4 and 7.1 Hz; 1H; H-4’ ribose 
ring), 4.02 (dd; J = 9.3 and 4.5; 1H; H-3’ ribose ring), 5.73 (d; 
J = 4.1; 1H; H-2’ ribose ring), δ 8.40 (s; 1H; H-6 uracil ring). 
5-Bromo-3’,4’,6’-O-triacetyl-uridine or 5-Bromo-uri-
dine triacetate (M1)
The derivative was obtained coupling the halogenation 
and per-acetylation reactions (see reaction scheme, fig-
ure 1), this was isolated as pale-yellow solid (quantitative 
yield). 1H-RMN (300MHz, CDCl3), δ ppm (multiplicity; 
integration; J (Hz); position): 2.14 (d; 6H; H-2” (α protons) 
acetyl linked to O-3’ and O-6’ ribose ring), 2.18 (s; 3H; H-2” 
acetyl linked to O-4’ ribose ring), 4.41 (m; 3H; H-5’ and H-6’ 
ribose ring), 5.38 (m; 2H, H-3’ and H-4’ ribose ring), 6.12 (d; 
1H; H-2’ ribose ring), 7.87 (s; 1H; H-6 uracil ring). 13C-RMN 
(75MHz, CDCl3), δ ppm (integration; position): 20.42 (1C; 
C-2” (α carbon) acetyl linked to O-6’ ribose ring), 20.52 (1C; 
position C-2” acetyl linked to O-3’ ribose ring), 20.94 (1C; 
C-2” acetyl linked to O-4’ ribose ring), 62.96 (1C; C-6’ ri-
bose ring), 70.07 (1C; C-4’ ribose ring), 73.14 (1C; C-3’ ribose 
ring), 80.37 (1C; C-5’ ribose ring), 87.37(1C; C-2’ (anomeric 
carbon) ribose ring), 97.98 (1C; 5-C (halogenated position) 
uracil ring), 138.62 (1C; 6-C uracil ring), 149.70 (1C; 2-C ura-
cil ring), 158.71 (1C; 4-C uracil ring), 169.71 (2C; C-1” acetyl 
linked to O-3’ and O-4’ ribose ring), 170.16 (1C; C-1” acetyl 
linked to O-6’ ribose ring). Calculated for C15H17BrN2O9: 
449.2074; found, 472.2 [M+Na]+.
5-Chloro-3’,4’,6’-O-triacetyl-uridine or 5-Chloro-uri-
dine triacetate (M2)
The derivative was obtained coupling the halogenation 
and per-acetylation reactions (see reaction scheme, fig-
ure 1), this was isolated as pale-yellow solid (quantitative 
yield). 1H-RMN (300MHz, CDCl3), δ ppm (multiplicity; 
integration; J (Hz); position): 2.16 (d; 6H; H-2” (α protons) 
acetyl linked to O-3’ and O-6’ ribose ring), 2.22 (s; 3H; H-2” 
acetyl linked to O-4’ ribose ring), 4.42 (m; 3H; H-5’ and H-6’ 
ribose ring), 5.38 (m; 2H; H-3’ and H-4’ ribose ring), 6.11 (d; 
1H; H-2’ ribose ring), 7.78 (s; 1H; H-6 uracil ring).13C-RMN 
(75MHz, CDCl3), δ ppm (integration; position): 20.41 (1C; 
C-2” (α carbon) acetyl linked to O-6’ ribose ring), 20.51 (1C; 
C-2” acetyl linked to O-3’ ribose ring), 20.85 (1C; C-2” acetyl 
linked to O-4’ ribose ring), 62.91 (1C; C-6’ ribose ring), 70.03 
(1C; C-4’ ribose ring), 73.11 (1C; C-3’ ribose ring), 80.23 (1C; 
C-5’ ribose ring), 87.37(1C; C-2’ (anomeric carbon) ribose 
ring), 110.13 (1C; 5-C (halogenated position) uracil ring), 
135.99 (1C; 6-C uracil ring), 149.41 (1C; 2-C uracil ring), 
149Ars Pharm. 2017; 58(4): 145-154
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158.61 (1C; 4-C uracil ring), 169.70 (2C; C-1” acetyl linked 
to O-3’ and O-4’ ribose ring), 170.13 (1C; C-1” acetyl linked 
to O-6’ ribose ring). Calculated for C15H17ClN2O9: 404.7564; 
found, 427.8 [M+Na]+.
4-N-acetyl-3’,4’,6’-O-triacetyl-cytarabine (D7)
The product was obtained as described in per-acetylation 
reaction (see scheme reaction in figure 2) and was isolated 
as yellow solid in quantitative yield. 1H NMR (300 MHz; 
CDCl3), δ ppm (multiplicity; integration; J (Hz); group; po-
sition) 1.89 (s; 3H; H-2” acetyl linked to O-3’ arabinofurano-
syl ring (AF.R)), 2.09-1.98 (m; 6H; H-2” acetyl linked to O-4’ 
and O-6’ AF.R), 2.21 (s; 3H; H-2” acetyl linked to N-4 cyto-
sine ring), 4.16 (t; 1H; J=10.5; H-5’ AF.R), 4.33 (t; 2H; J=12.3; 
H-6’ AF.R), 5.04 (d; 1H; J=10.8; H-4’ AF.R), 5.49 (d; 1H; J=2.5; 
H-3’ AF.R), 6.29 (d; 1H; J=3.4; H-2’ AF.R), 7.43 (d; 1H; J=7.6 
Hz; H-5 cytosine ring), 7.88 (d; 1H; J=7.6 Hz; H-6 cytosine 
ring). 13C NMR (75 MHz, CDCl3), δ ppm (integration; po-
sition): 20.38 (1C; C-2” acetyl linked to O-3’ of AF.R), 20.60 
(1C; C-2” acetyl linked to O-4’ of AF.R), 20.70 (1C; C-2” 
acetyl linked to O-6’ of AF.R), 24.75 (1C; C-2” acetyl linked 
to 4-N cytosine ring), 62.77 (1C; C-6’ AF.R), 73.97 (1C; C-3’ 
AF.R), 76.32 (1C; C-4’ AF.R), 81.05 (1C; C-5’ AF.R), 85.71 (1C; 
C-2’ AF.R), 96.45 (1C; 5-C cytosine ring), 144.77 (1C; 6-C cy-
tosine ring), 154.72 (1C, 2-C cytosine ring), 163.25 (1C, 4-C 
cytosine ring), 168.26 (1C; C-1” acetyl linking to O-4’ of 
AF.R), 169.64 (1C; C-1” acetyl linked to O-3’ AF.R), 170.55 
(1C; C-1” acetyl linked to O-6’ AF.R), 171.63 (1C; C-1” acetyl 
linked to 4-N cytosine ring). ESI-MS (positive mode) m/z: 
Calculated for C17H21N3O9: 411.3634; found, 434.1 [M+Na]
+.
Figure 2. Reaction scheme and chemical structures of per-acetylated cytarabine.
5-Bromo-4-N-acetyl-3’,4’,6’-O-triacetyl-cytarabine 
(M3)
The derivative was obtained coupling the halogenation 
and per-acetylation reactions (see reaction scheme, figure 
2) and was isolated as yellow solid (quantitative yield). 1H 
NMR (300 MHz; CDCl3), δ ppm (multiplicity; integration; 
J (Hz); group; position) 1.88 (s; 3H; H-2” of acetyl linked 
to O-3’ arabinofuranosyl ring (AF.R)), 2.06-1.99 (m; 6H; 
H-2” acetyl linked to O-4’ and O-6’ AF.R), 2.22 (s; 3H; H-2” 
acetyl linked to N-4 cytosine), 4.29 (m; 3H; H-5’ and H-6’ 
AF.R), 5.09 (d; 1H; J=10.7; H-4’ AF.R), 5.52 (d; 1H; J=2.4; H-3’ 
AF.R), 6.27 (d; 1H; J=3.4; H-2’ AF.R), 8.01(s; 1H; H-6 cyto-
sine ring). 13C NMR (75 MHz, CDCl3), δ ppm (integration; 
position): 20.49 (1C; C-2” acetyl linked to O-3’ AF.R), 20.72 
(1C; C-2” acetyl linked to O-4’ AF.R), 20.81 (1C; C-2” acetyl 
linked to O-6’ AF.R), 24.88 (1C; C-2” acetyl linked to 4-N 
cytosine ring), 62.84 (1C; C-6’ AF.R), 73.92 (1C; C-3’ AF.R), 
76.42 (1C; C-4’ AF.R), 81.12 (1C; C-5’ AF.R), 85.53 (1C; C-2’ 
AF.R), 96.33 (1C; 5-C cytosine ring), 144.67 (1C; 6-C cytosine 
ring), 155.04 (1C, 2-C cytosine ring), 163.12 (1C, 4-C cyto-
sine ring), 168.38 (1C; C-1” acetyl linking to O-4’ of AF.R), 
169.72 (1C; RO-C=O; position C-1” of acetyl linked to O-3’ 
of AF.R), 170.63 (1C; C-1” acetyl linked to O-6’ AF.R), 171.45 
(1C; C-1” acetyl linked to N-4 cytosine ring). ESI-MS (pos-
itive mode) m/z: Calculated for C17H20BrN3O9: 490.2594; 
found, 513.3 [M+Na]+.
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5-Chloro-4-N-acetyl-3’,4’,6’-O-triacetyl-cytarabine 
(M4)
The derivative was obtained coupling the halogenation 
and per-acetylation reactions (see reaction scheme, figure 
2) and was isolated as yellow solid (quantitative yield). 1H 
NMR (300 MHz; CDCl3), δ ppm (multiplicity; integration; J 
(Hz); group; position) 1.89 (s; 3H; H-2” acetyl linked to O-3’ 
arabinofuranosyl ring (AF.R)), 2.07-1.98 (m; 6H; H-2” acetyl 
linked to O-4’ and O-6’ AF.R), 2.20 (s; 3H; H-2” of acetyl 
linked to 4-N AF.R), 4.27 (m; 2H; H-5’ and H-6’ AF.R), 5.06 
(d; 1H; J=10.8; H-4’ AF.R), 5.49 (d; 1H; J=2.6; H-3’ AF.R), 6.27 
(d; 1H; J=3.3; H-2’ AF.R), 7.96 (s; 1H; H-6 cytosine ring). 13C 
NMR (75 MHz, CDCl3), δ ppm (integration; position): 20.17 
(1C; C-2” acetyl linked to O-3’ AF.R), 20.18 (1C; C-2” acetyl 
linked to O-4’ AF.R), 20.27 (1C; C-2” acetyl linked to O-6’ 
AF.R), 24.32 (1C; C-2” acetyl linked to N-4 cytosine ring), 
62.35 (1C; C-6’ AF.R), 73.54 (1C; C-3’ AF.R), 75.97 (1C; C-4’ 
AF.R), 80.26 (1C; C-5’ AF.R), 84.99 (1C; C-2’ AF.R), 104.15 
(1C; C-5 cytosine ring), 144.34 (1C; C-6 cytosine ring), 154.59 
(1C, C-2 cytosine ring), 162.52 (1C; C-4 cytosine ring), 167.84 
(1C; C-1” acetyl linking to O-4’ AF.R), 169.22 (1C; RO-C=O; 
C-1” acetyl linked to O-3’ AF.R), 170.12 (1C; C-1” acetyl 
linked to O-6’ AF.R), 171.21 (1C; C-1” acetyl linked to N-4 
cytosine ring). ESI-MS (positive mode) m/z: Calculated for 
C17H20ClN3O9: 445.8084; found, 468,8 [M+Na]
+.
Viability assay
Cell lines employed: CHO-K1 (Chinese Hamster Ovary, 
ATCC N° CCL61) and MCF-7 (human breast adenocarci-
noma, ATCC N° HTB22). Ham F12 (Sigma) and DMEM 
(Sigma) were used as culture media and fetal bovine serum 
(FBS, Gibco, Brazil) was implemented as a supplement. 
Penicillin and streptomycin (Gibco) were used as antibacte-
rial and antifungal agents, respectively. The (3-[4,5-dimeth-
ylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, thiazolyl 
blue) (MTT, Sigma). DMSO 99.9% purity (Sigma) and 
2-propanol 98% purity (J. T. Baker), were employed at rea-
gent grade. The absorbance was read in Multiskan FC Mi-
croplate Photometer–ThermoScientific spectrophotometer.
Cell culture
CHO-K1 and MCF-7 cell lines in exponential phase were 
cultured in Ham F-12 or DMEM medium, which were sup-
plemented with FBS at 5% and treated with penicillin 100 
U/mL and streptomycin 100 µg/mL. The cultures were in-
cubated at 37°C for 48 hours. MCF-7 cell line was incubated 
in wet atmosphere with 5% CO2.
MTT assay
MCF-7 and CHO-K1 cultured cells were disseminated in 
96 well plates at a cell density of 5x103 and 6x103 cells per 
well, respectively. The cultures were treated with concen-
trations of 1, 10 and 100 µM of uridine, cytarabine or their 
derivatives and incubated at 37°C for 48 hours, followed 
by an addition of 10 µL of MTT (5 mg/mL) to each plate, 
which were, additionally, incubated in the dark at 37ºC for 
4 hours. Subsequently, 100 μL of acidified isopropanol were 
added to each plate and were agitated at room tempera-
ture for 1 hour. The absorbance was measured at 570 nm 
and cell viability percentage was calculated by three rep-
licas of each treatment. Results were indicated with mean 
and standard deviation (X±SD) in at least two experiments. 
Statistical analysis was performed with ANOVA two-way, 
Bonferroni test with p<0.05 with GraphPad Prism Version 
5.0 Software.
RESULTS 
Chemical
The halogenation reaction with NCS and NBS allowed the 
selective substitution on the 5-position of uracil and cyto-
sine ring of each nucleoside with quantitative conversions. 
As the esterification performed with acetic anhydride as 
reagent and solvent does not require heating or aggressive 
mediums (acidic or basic), it is an ideal reaction for high-
ly acid labile substrates or thermo-labile, like nucleosides. 
This reaction is assisted with a nucleophilic catalyst, allow-
ing the per-acylation of nucleosides, achieving the esters 
formation of all hydroxyl groups of ribose and arabino-
furanosyl rings of uridine and cytarabine, respectively, and 
the amide formation on amine group of cytosine ring in the 
second nucleoside4,21. 
The three hydroxyl groups esterification in the uridine, is 
simple because the OH-3’ and OH-4’ position is Z among 
them, and E regarding the ribose ring and other hydrox-
yl group (position 6’); therefore, acetyl groups are orient-
ed in the space like scissors. Nevertheless, this reaction in 
the cytarabine, is very complex as the hydroxyl groups of 
same positions are E, and the OH-3’ is oriented Z in relation 
to the cytosine ring; therefore, the steric interactions are 
strong, even so, it was possible to obtain the per-acetylated 
derivative of cytarabine considering that the acetyl group is 
small and the anhydride acetic is used in higher amounts.
The halogenated and per-acetylated derivatives were 
identified comparing 1H-NMR, 13C-NMR, 1H-1H COSY, 
HSQC and HMBC uridine and cytarabine data (300 MHz 
and 600 MHz; DMSO-d6). 1H-NMR and 13C-NMR signals 
for the monosaccharide rings and nitrogenous bases of the 
nucleoside derivatives, presented a significant deviation on 
their chemical shift from the respective substrates (uridine 
and cytarabine). The NMR data and masses founded with 
the MS spectrometry fit with the structures proposed. 
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Viability assay
The results of cell viability, obtained by MTT assay with 
uridine and cytarabine halogenated and their per-acetylat-
ed derivatives are shown in figure 3. The per-acetylated 
derivatives of uridine and cytarabine, did not present sig-
nificant inhibition of cell viability with the cell lines imple-
mented (CHO-K1 and MCF-7) at the lowest concentrations 
evaluated (1 µM and 10 µM). Nevertheless, a higher inhi-
bition of cell viability on both cell lines was observed for 
the peracetylated and halogenated nucleoside evaluated. 
Moreover, only the uridine acetonide exhibited a signifi-
cant inhibition (higher than 80%) of cellular viabilities of 
CHO-K1 and MCF-7 cell lines. The uridine presented a de-
crease (around 20%) on MCF-7 cell viability at the highest 
concentration tested (100 µM).
Figure 3. Cell viability of per-acetylated nucleoside (C1 and D7) an halogenated and per-acetylated derivatives 
(M1-M4), assessed with 1μM, 10μM and 100μM of the compounds by 48 hours. A. CHO-K1 cell line. B. MCF-7 
cell line. C- (Control without treatment) and Urd: uridine. Data are shown as mean ± S.D. Statistical significance 
was calculated with p<0.05.
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DISCUSSION
Chemical
The per-acetylated products were obtained in quantitative 
yields, possibly due to the use of acetic anhydride as rea-
gent in the acylation and in the solvent mixture, thus the 
effective collisions among the substrate and reagent were 
increased significantly. Although the amount of substrate 
dissolved was low, the products are highly soluble in the 
reaction; this property causes the displacement to the right 
of the equilibrium between solid and dissolved substrates. 
Moreover, the use of the nucleophilic catalyst (DMAP) in-
creases the rate reaction producing a higher product forma-
tion. As the acylation reagent was in vast amount, the inter-
mediate performed with the DMAP, is generated quickly 
and continuously so is available for the nucleophilic attack 
by alcohol or amine groups of the nucleosides4,21. 
The COSY H-H spectrum for 3’,4’,6’-O-acetyl-uridine in 
DMSO-d6 presents at high-field, a multiplet coupling with 
shift δ=4.25 ppm equivalent to three protons (correspond-
ing to overlapping of H-5’ and H-6’ protons of ribose ring) 
with a high deshielding signal δ=5.44 ppm (H-3’). Further-
more, this proton presents two couplings, with a shielding 
signal localized at δ=5.33 (H-4’) and other highly deshield-
ed signal δ=5.87 ppm corresponding to an anomeric pro-
ton (H-2’) of the ribose ring. At down-field, a coupling be-
tween the proton appeared at δ=5.72 ppm (H-5 uracil ring) 
with the highest deshielding δ=7.69 (H-6 uracil ring). The 
COSY H-H spectrum for the 4-N-acetyl-3’,4’,6’-O-triacetyl-
cytarabine in CDCl3 shows at high field that the signals for 
the H-5’ and H-6’protons of arabinofuranosyl ring are not 
overlapped, neither are the H-3’and H-4’ protons. How-
ever, it is possible to observe a coupling between protons 
with higher shielding δ=4.16 ppm (H-5’) of arabinofura-
nosyl ring and the signals at δ=4.33 ppm (H-6’). Moreover, 
an intense coupling is observed for the proton localized at 
δ=5.49 ppm (H-3’) with a high deshielding signal, δ=6.29 
ppm corresponding to an anomeric proton (H-2’) of the 
ribose ring. At down-field, it is observed a coupling be-
tween two deshielding signals, localized at δ=7.43 ppm and 
δ=7.88, corresponding to H-5 and H-6 protons of cytosine 
ring, respectively. 
In the spectrums of the halogenated and per-acetylated 
derivatives of nucleoside the coupling at down-field dis-
appeared therefore, the signal for the H-6 proton is see as 
singlete.
The HSQC spectrum for 3’,4’,6’-O-triacetyl-uridine in 
DMSO-d6, presents at high-field the expected couplings 
between the proton signals with highest shielding of the 
methyl groups and the highest shielding carbons, cor-
responding to alpha position of the acetyl groups. Addi-
tionally, two couplings by the multiplet corresponding to 
H-5’ and H-6’ protons, with two kinds of carbons: a highly 
shielding carbon δ=62.61 ppm and another highly deshield-
ing carbon δ=80.18 ppm, corresponding to C-6’ and C-5’ 
carbons of the same monosaccharide, respectively. Fur-
thermore, it is possible to perceive the expected couplings 
for signals of the H-4’, H-3’ and H-2’ protons of the ribose 
ring with three kinds of deshielding carbons, localized at 
δ=70.47 ppm, δ=72.61 ppm and δ=87.17, corresponding to 
C-4’, C-3’ and C-2’ carbons of the monosaccharide, respec-
tively. At down-field, it is noted a coupling among the high-
est deshielding proton (H-6) and a high deshielded carbon, 
localized at δ=139.12 ppm (C-6 carbon of uracil ring). The 
HSQC spectrum for the 4-N-acetyl-3’,4’,6’-O-triacetyl-
cytarabine in CDCl3, shows at high field a coupling by the 
shielding proton at δ=4.16 ppm (H-5’) of the arabinofura-
nosyl ring with a high deshielding carbon δ=81.05 ppm, 
corresponding to C-5’ of the monosaccharide. In addition, 
it is possible to notice a coupling between the protons with 
chemical shift at δ=4.33 ppm (H-6’of arabinofuranosyl ring) 
and the shielding carbon at δ=62.77 ppm, corresponding to 
C-6’ of the monosaccharide, as well the expected couplings 
between the proton signals H-4’, H-3’ and H-2’ of arabino-
furanosyl ring and the carbons corresponding to the same 
position of the monosacharide. At down-field, a coupling is 
detected for the proton signal of the H-5 citosine ring with 
deshielding carbon localized at δ=96.45 ppm, correspond-
ing to C-5 of the same nitrogenus base and a second cou-
pling between the proton signal with highest deshielding 
of the citosine ring and the highest deshielding carbon with 
chemical shift at δ=144.77 ppm (C-6 of nitrogenus base).
In the spectrums for the halogenated and per-acetylated 
compounds at down field, it is noticed only the coupling 
between the highest deshielding proton (H-6) of the nitrog-
enous base ring and a high deshielding carbon with chem-
ical shift at δ=135-145 ppm corresponding to C-6 nitroge-
nous base ring.
Viability assay
The cytotoxic activity exhibited for the halogenated nucleo-
side and its per-acetylated derivatives has a non-significant 
effect. The negative result obtained is probably indicative of 
a phenomenon of resistance to the nucleoside for the MCF-7 
cell line. This phenomenon may respond to three factors: an 
overexpression of receptors of tyrosine kinase (ErbB) that 
can accelerate the cell cycle and deactivate the cell cycle de-
tainment performed by nucleosides22; an overproduction of 
the enzymatic targets pyr1-3 (the multifunctional polypep-
tide which comprises carbamyl-phosphate synthetase (EC 
2.7.2.5), aspartate transcarbamylase (EC 2.1.3.2), dihydro-
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orotase (EC 1.3.3.1); pyr5,6 (enzyme complex comprising 
orotate phosphoribosyltransferase (EC 2.4.2.10) and oro-
tidine-5’-phosphate decarboxylase (EC 4.1.1.2), in which 
generally participates in the novo synthesis of pyrimidine 
nucleosides and in which the larger amounts of enzymes 
cause the inhibition of nucleoside savage route23; and when 
the transmembrane channels transport (of phosphoglyco-
protein nature) for the nucleosides are overexpressed, as 
this can cause a reduction in the nucleoside cellular uptake 
from the exterior of the cell24. 
The uridine acetonide showed a higher inhibition effect on 
viability of MCF-7 cell line than the uridine. This can be 
explained by the simple activation (phosphorylation) over 
OH-6’ and the hydrolysis of acetonide group, also the sub-
stituent in the acetonide derivate can provide a lipophilici-
ty (LogP(uridine-acetonide) = 0.20, LogP(uridine) = -1.61, LogP (cytarabine) 
= -1.93, predicted by ACD/Labs and ChemAxon®), hence 
the solubility and/or interaction with the lipophilic phase 
of the cellular membrane can increase. In the per-acetylated 
and halogenated nucleoside, the adjacent chains are very 
small, thus the hydrolysis of the acyls groups can be via-
ble and thermodynamically favorable, but this process may 
result slower than the phosphorylation in the same posi-
tion3,4,8-10. Furthermore, the per-acetylated derivatives of 
uridine and cytarabine did not show a higher lipophilicity 
(LogP(uridine-triacetate) = -0.11, predicted by ACD/Labs and Che-
mAxon®) than the nucleosides, therefore the interaction 
with the lipophilic phase of membrane cell was lower than 
in the acetonide8-10,14. Additionally, some of the nucleoside 
derivatives, particularly with voluminous substituents, 
present a great steric impediment, which can have a inhibi-
tory effect on the hydrolysis of 6'-acyl-ester group of the ri-
bose, exerted by esterase enzyme and the phosphorylation 
over OH-6’ of the ribose ring, is essential for the activation 
and action mechanism of the nucleosides3,4,8,15.
CONCLUSIONS
The methods used allowed to obtain the acetylation of all 
hydroxyl and/or amine groups of substrates of the nucle-
oside type and the mono-halogenation of the nitrogenous 
base. 
No significant effects on cell viability for the nucleoside 
and derivatives halogenated and per-acetylated were ob-
served with p<0.05. Moreover, these compounds did not 
present a dose-response relationship, the uridine 3’,4’-ace-
tonide showed a differential effect and a higher activity on 
cell viability on the MCF-7 human cancer breast cell line 
than on the CHO-K1 cell line. Nevertheless, the derivate 
3’,4’-acetonide 6'-O-succinyl uridine showed lower activity 
on both cell lines than the uridine 3’,4’-acetonide. Further-
more, the breast cancer cell line MCF-7 used, according to 
the results, exhibits possible resistance to nucleosides and/
or analogs. The per-acetylated and halogenated derivatives 
of the nucleosides are voluminous and present low activity, 
hence the decreased activation and the subsequent cytotox-
ic activity.
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